Digital therapies

with clinically

proven efficacy

Orexo´s digital therapies deliver therapeutic interventions to patients to prevent, manage, or treat a medical disorder or disease. The therapies are available for patients in their own privacy 24/7 and can be used as a standalone treatment or together with traditional drugs. Its efficacy has been demonstrated in numerous published clinical trials including thousands of patients.

The therapies are developed based on established cognitive-behavioral therapy technique which is a goal-oriented psychotherapy treatment that takes a hands-on, practical approach to problem-solving. The aim is to provide support and change patterns of thinking or behavior that are behind patients difficulties.

Partnership with Sober Grid 

Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies VORVIDA® and DEPREXIS®

Pipeline of Digital Therapies 

Digital Therapies
Technical development
Approved and/or Launched
DEPREXIS® Depression
Partner: GAIA AG
VORVIDA® Alcohol misuse, incl. alcohol use disorder
Partner: GAIA AG
MODIA™ Opioid addiction
Partner: GAIA AG
MODIA™ is being tested in a pivotal study

MODIA™ is being tested in a pivotal study

Large pivotal study initiated in June 2021, where the efficacy of MODIA™ is evaluated along with bup/nal pharma treatment.

World-leading technology

World-leading technology

Our digital therapies are fully automated developed by GAIA and based on its proprietary artificial intelligence (AI)-expert system, broca®.

DEPREXIS® - one of the most clinically tested digital therapies

DEPREXIS® - one of the most clinically tested digital therapies

DEPREXIS® effectiveness in managing the symptoms of depression has been evaluated and published in 11 randomized clinical trials (RCTs) including more than 2,800 patients.